An analysis study observed an increase in thromboembolic events in patients aged between 65 and 70 in the bevacizumab group compared with the controlled group On, 28 but this has not been determined in retrospect no other study.29 Although erh Increase the toxicity in t GSK1120212 MAPK inhibitor Older patients in clinical studies are included to find compared to younger patients, the addition of biological therapies such as bevacizumab adds to patients at the age of toxicity t uniquely determined in this population that must be considered when treating older patients with metastatic colorectal carcinoma. For example, in the subgroup analysis of the test AGITG MAX grades May 3, 29 toxicity of t in patients over 75 treated with chemotherapy plus bevacizumab in age from 9.7% showed an incidence of thrombosis, thrombosis or embolism, an incidence of 4.
8 % of cardiac ish anemia, Fostamatinib 1025687-58-4 myocardial infarction, angina pectoris, or a 3.2% incidence of arterial thromboembolic events, or a 3.2% incidence of bleeding. In our study 43% of patients discontinued treatment because of side effects, especially Neurotoxizit t have dropped, but that does not found Hrden the results of treatment. Probably, patients with mCRC Older people and their Doctors tend to discontinue treatment, so some researchers have suggested.26 Komorbidit t is repeatedly cited as a reason not to treat Older patients. However, the impact that comorbidities should have on decision-making processes are not clearly defined. One third of the patients in our study pr Presents two or more comorbid disorders.
No significant correlation between Komorbidit t and the parameters of efficacy or safety found, but the numbers m for may have not enough for such analyzes. These results are consistent with other studies that have shown no evidence of interaction between Komorbidit soldering and survive to the age and toxicity.48 A m Possible explanation Tion k Nnte be that the general health of the participants in the recruited clinical trial was relatively good, because most patients had an ECOG first Some researchers suggest that assessment of functional status by the ECOG scale does not seem to be as effective in patients who are you Older than in younger Bev Lkerung because comorbidities in Older people can use this parameter st Ren k. 49 A RESTRICTIONS LIMITATION our study is that Komorbidit Th were not controlled Strips with a validated method of specific geriatric assessment, so far as it can proposed.
30 Komorbidit t the result of several factors, such as that of the zinc Siege diagnosis of cancer, decreased use of chemotherapy or increased Hte toxicity in Th connection with treatment, or because it acts as a competing causes of death. The effect of Komorbidit t on earnings can be influenced by other factors such as age or performance status. Nevertheless, the use of chemotherapy and outcome in cancer patients with Komorbidit Th rule are lower, although the evidence Descr Nkt on the ratio Ratio determined between use and reduced survival rate is lower, and prospective studies are needed. A recently published study examined the randomized Software released r of chemotherapy in older patients and / or fragile mCRC.50 were reduced with two main objectives defined: the addition of oxaliplatin to 5-FU, the one proposed some advantages in terms of PFS and significant increase in the ORR, and the replacement of FU with capecitabine, which showed no influence on The quality of life t. In this